Synergistic Lung Tissue Engineering Platform

A novel, integrated system for generating lung-like epithelium by combining pluripotent stem cell culture with advanced technologies such as artificial intelligence, blockchain, and IoT, enabling personalized lung tissue models, targeted therapy, and secure data management.

The original patent disclosed methods and systems for growing, expanding, and/or obtaining 3-dimensional lung-like epithelium. However, the limitations of the original patent include the lack of scalability, personalized medicine capabilities, and secure data management. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful system.

The synergistic lung tissue engineering platform comprises a pluripotent stem cell culture, a Wnt signaling pathway activator, and an artificial intelligence module for monitoring and optimizing cell differentiation. The platform also integrates a blockchain-based secure data storage system for tracking and sharing patient data, enabling personalized lung tissue models. Additionally, the platform incorporates an IoT-based sensor system for real-time monitoring of the culture environment and a machine learning algorithm for predicting optimal culture conditions. The platform can be used to create compositions for treating lung diseases, which include lung-like epithelium derived from pluripotent stem cells, a nanomaterial-based delivery system for targeted therapy, and a blockchain-based supply chain management system for tracking the origin and distribution of the composition.

The new inventive concept is novel and non-obvious compared to the original patent because it integrates distinct technologies such as artificial intelligence, blockchain, and IoT to create a more powerful system. The inventive step lies in the synergistic combination of these technologies to enable personalized lung tissue models, targeted therapy, and secure data management.

Alternative embodiments of the synergistic lung tissue engineering platform could include the use of different types of stem cells, such as adult stem cells or induced pluripotent stem cells. Additionally, the platform could be adapted for use with other types of tissue, such as cardiac or neural tissue. The platform could also be integrated with other advanced technologies, such as CRISPR gene editing or synthetic biology.

The synergistic lung tissue engineering platform has significant commercial potential in the fields of regenerative medicine, personalized medicine, and pharmaceuticals. The platform could be used to develop new treatments for lung diseases, such as chronic obstructive pulmonary disease (COPD) or cystic fibrosis. Additionally, the platform could be used to develop personalized lung tissue models for drug testing and development, reducing the need for animal testing and accelerating the drug development process.